Journal article
Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel
Abstract
BACKGROUND: Topotecan has single-agent activity in recurrent ovarian cancer. It was evaluated in a novel combination compared with standard frontline therapy.
METHODS: Women aged 75 years or younger with newly diagnosed stage IIB or greater ovarian cancer, Eastern Cooperative Oncology Group Performance Status of 1 or less, were stratified by type of primary surgery and residual disease, treatment center, and age; then randomly assigned to one …
Authors
Hoskins P; Vergote I; Cervantes A; Tu D; Stuart G; Zola P; Poveda A; Provencher D; Katsaros D; Ojeda B
Journal
Journal of the National Cancer Institute, Vol. 102, No. 20, pp. 1547–1556
Publisher
Oxford University Press (OUP)
Publication Date
October 20, 2010
DOI
10.1093/jnci/djq362
ISSN
0027-8874